

## Special Issue

# A New Era in Treatment of Early-Stage Non-Small Cell Lung Cancer

### Message from the Guest Editor

The standard of care for early-stage non-small cell lung cancer (NSCLC) has changed dramatically with increasing evidence for minimally invasive surgery, such as video-assisted thoracic surgery (VATS) and robotic-assisted thoracic surgery (RATS); sublobar resection, such as segmentectomy or wedge resection; and perioperative immunotherapy or targeted therapy. We are pleased to invite you to submit your experimental and theoretical results regarding new treatments for early-stage NSCLC. Full experimental details must be provided so that the results can be reproduced. In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following:

- Minimally invasive surgery for lung cancer.
- Sublobar resection for early-stage NSCLC.
- Perioperative therapy for early-stage NSCLC.

I look forward to receiving your contributions.

---

### Guest Editor

Prof. Dr. Tsutani Yasuhiro

Division of Thoracic Surgery, Department of Surgery, Kindai University Faculty of Medicine, 377-2 Ohno-Higashi, Osakasayama 589-8511, Japan

---

### Deadline for manuscript submissions

25 February 2025



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.5  
CiteScore 8.0  
Indexed in PubMed



[mdpi.com/si/194184](https://mdpi.com/si/194184)

*Cancers*

MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.5  
CiteScore 8.0  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)